Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents (Q4967095)
From MaRDI portal
scientific article; zbMATH DE number 7075686
Language | Label | Description | Also known as |
---|---|---|---|
English | Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents |
scientific article; zbMATH DE number 7075686 |
Statements
Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents (English)
0 references
2 July 2019
0 references
attributable toxicity
0 references
cancer phase I trials
0 references
continual reassessment method
0 references
copula type models
0 references
drug combination
0 references